Genmab · 2 weeks ago
Omnichannel Marketing Strategy Intern
Princeton, NJ
Internship
Hybrid
Intern
Start in 2026 SummerGenmab is an international biotechnology company dedicated to improving patient lives through innovative antibody therapeutics. The Omnichannel Marketing Strategy Intern will support the planning and execution of marketing initiatives across various channels, analyze performance metrics, and collaborate with cross-functional teams to enhance customer engagement strategies.
BiotechnologyHealth CareManufacturingMedical
No H1B
Responsibilities
Power Omnichannel Campaigns – Support the planning, execution, and optimization of marketing initiatives across email, web, media, and sales channels
Turn Data into Strategy – Analyze performance metrics, uncover insights, and help optimize engagement strategies that reach the right audience at the right time
Collaborate & Innovate – Work with brand marketing, digital operations, analytics, and external partners to align content and messaging for a seamless customer experience
Own Your Voice – Contribute ideas, help develop key presentations, and play an active role in shaping omnichannel best practices
Qualification
Required
Currently pursuing a Bachelor's or Master's degree in Marketing, Business, Communications, Digital Media, Advertising, or a related field
Strong organizational and time-management skills with the ability to manage multiple tasks and deadlines
Excellent verbal and written communication skills, with attention to detail
Proficiency in Microsoft Office Suite (Excel, PowerPoint, Outlook, Word)
Ability to work collaboratively in a team environment and communicate effectively across cross-functional teams
Preferred
Familiarity with omnichannel marketing concepts, website management, or digital campaign execution
Experience using marketing technology tools (preferred but not required)
Prior internship or coursework related to digital marketing, advertising, media planning, or analytics
Company
Genmab
Genmab is a biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer.
Founded in 1999
1001-5000 employees
Funding
Current Stage
Public CompanyTotal Funding
$11.7BKey Investors
Morgan Stanley Senior FundingGlaxoSmithKlineIndex Ventures
2025-11-18Post Ipo Debt· $6B
2025-09-29Post Ipo Debt· $5.5B
2010-07-01Post Ipo Equity· $134M
Leadership Team
Anthony Pagano
Chief Financial Officer
Anthony Mancini
EVP & Chief Operating Officer
Recent News
2026-01-19
2026-01-19
Pharma Letter
2026-01-18
Company data provided by crunchbase